\documentclass[11pt,twoside]{article}\makeatletter

\IfFileExists{xcolor.sty}%
  {\RequirePackage{xcolor}}%
  {\RequirePackage{color}}
\usepackage{colortbl}
\usepackage{wrapfig}
\usepackage{ifxetex}
\ifxetex
  \usepackage{fontspec}
  \usepackage{xunicode}
  \catcode`⃥=\active \def⃥{\textbackslash}
  \catcode`❴=\active \def❴{\{}
  \catcode`❵=\active \def❵{\}}
  \def\textJapanese{\fontspec{Noto Sans CJK JP}}
  \def\textChinese{\fontspec{Noto Sans CJK SC}}
  \def\textKorean{\fontspec{Noto Sans CJK KR}}
  \setmonofont{DejaVu Sans Mono}
  
\else
  \IfFileExists{utf8x.def}%
   {\usepackage[utf8x]{inputenc}
      \PrerenderUnicode{–}
    }%
   {\usepackage[utf8]{inputenc}}
  \usepackage[english]{babel}
  \usepackage[T1]{fontenc}
  \usepackage{float}
  \usepackage[]{ucs}
  \uc@dclc{8421}{default}{\textbackslash }
  \uc@dclc{10100}{default}{\{}
  \uc@dclc{10101}{default}{\}}
  \uc@dclc{8491}{default}{\AA{}}
  \uc@dclc{8239}{default}{\,}
  \uc@dclc{20154}{default}{ }
  \uc@dclc{10148}{default}{>}
  \def\textschwa{\rotatebox{-90}{e}}
  \def\textJapanese{}
  \def\textChinese{}
  \IfFileExists{tipa.sty}{\usepackage{tipa}}{}
\fi
\def\exampleFont{\ttfamily\small}
\DeclareTextSymbol{\textpi}{OML}{25}
\usepackage{relsize}
\RequirePackage{array}
\def\@testpach{\@chclass
 \ifnum \@lastchclass=6 \@ne \@chnum \@ne \else
  \ifnum \@lastchclass=7 5 \else
   \ifnum \@lastchclass=8 \tw@ \else
    \ifnum \@lastchclass=9 \thr@@
   \else \z@
   \ifnum \@lastchclass = 10 \else
   \edef\@nextchar{\expandafter\string\@nextchar}%
   \@chnum
   \if \@nextchar c\z@ \else
    \if \@nextchar l\@ne \else
     \if \@nextchar r\tw@ \else
   \z@ \@chclass
   \if\@nextchar |\@ne \else
    \if \@nextchar !6 \else
     \if \@nextchar @7 \else
      \if \@nextchar (8 \else
       \if \@nextchar )9 \else
  10
  \@chnum
  \if \@nextchar m\thr@@\else
   \if \@nextchar p4 \else
    \if \@nextchar b5 \else
   \z@ \@chclass \z@ \@preamerr \z@ \fi \fi \fi \fi
   \fi \fi  \fi  \fi  \fi  \fi  \fi \fi \fi \fi \fi \fi}
\gdef\arraybackslash{\let\\=\@arraycr}
\def\@textsubscript#1{{\m@th\ensuremath{_{\mbox{\fontsize\sf@size\z@#1}}}}}
\def\Panel#1#2#3#4{\multicolumn{#3}{){\columncolor{#2}}#4}{#1}}
\def\abbr{}
\def\corr{}
\def\expan{}
\def\gap{}
\def\orig{}
\def\reg{}
\def\ref{}
\def\sic{}
\def\persName{}\def\name{}
\def\placeName{}
\def\orgName{}
\def\textcal#1{{\fontspec{Lucida Calligraphy}#1}}
\def\textgothic#1{{\fontspec{Lucida Blackletter}#1}}
\def\textlarge#1{{\large #1}}
\def\textoverbar#1{\ensuremath{\overline{#1}}}
\def\textquoted#1{‘#1’}
\def\textsmall#1{{\small #1}}
\def\textsubscript#1{\@textsubscript{\selectfont#1}}
\def\textxi{\ensuremath{\xi}}
\def\titlem{\itshape}
\newenvironment{biblfree}{}{\ifvmode\par\fi }
\newenvironment{bibl}{}{}
\newenvironment{byline}{\vskip6pt\itshape\fontsize{16pt}{18pt}\selectfont}{\par }
\newenvironment{citbibl}{}{\ifvmode\par\fi }
\newenvironment{docAuthor}{\ifvmode\vskip4pt\fontsize{16pt}{18pt}\selectfont\fi\itshape}{\ifvmode\par\fi }
\newenvironment{docDate}{}{\ifvmode\par\fi }
\newenvironment{docImprint}{\vskip 6pt}{\ifvmode\par\fi }
\newenvironment{docTitle}{\vskip6pt\bfseries\fontsize{22pt}{25pt}\selectfont}{\par }
\newenvironment{msHead}{\vskip 6pt}{\par}
\newenvironment{msItem}{\vskip 6pt}{\par}
\newenvironment{rubric}{}{}
\newenvironment{titlePart}{}{\par }

\newcolumntype{L}[1]{){\raggedright\arraybackslash}p{#1}}
\newcolumntype{C}[1]{){\centering\arraybackslash}p{#1}}
\newcolumntype{R}[1]{){\raggedleft\arraybackslash}p{#1}}
\newcolumntype{P}[1]{){\arraybackslash}p{#1}}
\newcolumntype{B}[1]{){\arraybackslash}b{#1}}
\newcolumntype{M}[1]{){\arraybackslash}m{#1}}
\definecolor{label}{gray}{0.75}
\def\unusedattribute#1{\sout{\textcolor{label}{#1}}}
\DeclareRobustCommand*{\xref}{\hyper@normalise\xref@}
\def\xref@#1#2{\hyper@linkurl{#2}{#1}}
\begingroup
\catcode`\_=\active
\gdef_#1{\ensuremath{\sb{\mathrm{#1}}}}
\endgroup
\mathcode`\_=\string"8000
\catcode`\_=12\relax

\usepackage[a4paper,twoside,lmargin=1in,rmargin=1in,tmargin=1in,bmargin=1in,marginparwidth=0.75in]{geometry}
\usepackage{framed}

\definecolor{shadecolor}{gray}{0.95}
\usepackage{longtable}
\usepackage[normalem]{ulem}
\usepackage{fancyvrb}
\usepackage{fancyhdr}
\usepackage{graphicx}
\usepackage{marginnote}

\renewcommand{\@cite}[1]{#1}


\renewcommand*{\marginfont}{\itshape\footnotesize}

\def\Gin@extensions{.pdf,.png,.jpg,.mps,.tif}

  \pagestyle{fancy}

\usepackage[pdftitle={Plasma Uric Acid Levels in Relation to Plasma Cholesterol Levels in Type-2 Diabetes Mellitus},
 pdfauthor={}]{hyperref}
\hyperbaseurl{}

	 \paperwidth210mm
	 \paperheight297mm
              
\def\@pnumwidth{1.55em}
\def\@tocrmarg {2.55em}
\def\@dotsep{4.5}
\setcounter{tocdepth}{3}
\clubpenalty=8000
\emergencystretch 3em
\hbadness=4000
\hyphenpenalty=400
\pretolerance=750
\tolerance=2000
\vbadness=4000
\widowpenalty=10000

\renewcommand\section{\@startsection {section}{1}{\z@}%
     {-1.75ex \@plus -0.5ex \@minus -.2ex}%
     {0.5ex \@plus .2ex}%
     {\reset@font\Large\bfseries}}
\renewcommand\subsection{\@startsection{subsection}{2}{\z@}%
     {-1.75ex\@plus -0.5ex \@minus- .2ex}%
     {0.5ex \@plus .2ex}%
     {\reset@font\Large}}
\renewcommand\subsubsection{\@startsection{subsubsection}{3}{\z@}%
     {-1.5ex\@plus -0.35ex \@minus -.2ex}%
     {0.5ex \@plus .2ex}%
     {\reset@font\large}}
\renewcommand\paragraph{\@startsection{paragraph}{4}{\z@}%
     {-1ex \@plus-0.35ex \@minus -0.2ex}%
     {0.5ex \@plus .2ex}%
     {\reset@font\normalsize}}
\renewcommand\subparagraph{\@startsection{subparagraph}{5}{\parindent}%
     {1.5ex \@plus1ex \@minus .2ex}%
     {-1em}%
     {\reset@font\normalsize\bfseries}}


\def\l@section#1#2{\addpenalty{\@secpenalty} \addvspace{1.0em plus 1pt}
 \@tempdima 1.5em \begingroup
 \parindent \z@ \rightskip \@pnumwidth 
 \parfillskip -\@pnumwidth 
 \bfseries \leavevmode #1\hfil \hbox to\@pnumwidth{\hss #2}\par
 \endgroup}
\def\l@subsection{\@dottedtocline{2}{1.5em}{2.3em}}
\def\l@subsubsection{\@dottedtocline{3}{3.8em}{3.2em}}
\def\l@paragraph{\@dottedtocline{4}{7.0em}{4.1em}}
\def\l@subparagraph{\@dottedtocline{5}{10em}{5em}}
\@ifundefined{c@section}{\newcounter{section}}{}
\@ifundefined{c@chapter}{\newcounter{chapter}}{}
\newif\if@mainmatter 
\@mainmattertrue
\def\chaptername{Chapter}
\def\frontmatter{%
  \pagenumbering{roman}
  \def\thechapter{\@roman\c@chapter}
  \def\theHchapter{\roman{chapter}}
  \def\thesection{\@roman\c@section}
  \def\theHsection{\roman{section}}
  \def\@chapapp{}%
}
\def\mainmatter{%
  \cleardoublepage
  \def\thechapter{\@arabic\c@chapter}
  \setcounter{chapter}{0}
  \setcounter{section}{0}
  \pagenumbering{arabic}
  \setcounter{secnumdepth}{6}
  \def\@chapapp{\chaptername}%
  \def\theHchapter{\arabic{chapter}}
  \def\thesection{\@arabic\c@section}
  \def\theHsection{\arabic{section}}
}
\def\backmatter{%
  \cleardoublepage
  \setcounter{chapter}{0}
  \setcounter{section}{0}
  \setcounter{secnumdepth}{2}
  \def\@chapapp{\appendixname}%
  \def\thechapter{\@Alph\c@chapter}
  \def\theHchapter{\Alph{chapter}}
  \appendix
}
\newenvironment{bibitemlist}[1]{%
   \list{\@biblabel{\@arabic\c@enumiv}}%
       {\settowidth\labelwidth{\@biblabel{#1}}%
        \leftmargin\labelwidth
        \advance\leftmargin\labelsep
        \@openbib@code
        \usecounter{enumiv}%
        \let\p@enumiv\@empty
        \renewcommand\theenumiv{\@arabic\c@enumiv}%
	}%
  \sloppy
  \clubpenalty4000
  \@clubpenalty \clubpenalty
  \widowpenalty4000%
  \sfcode`\.\@m}%
  {\def\@noitemerr
    {\@latex@warning{Empty `bibitemlist' environment}}%
    \endlist}

\def\tableofcontents{\section*{\contentsname}\@starttoc{toc}}
\parskip0pt
\parindent1em
\def\Panel#1#2#3#4{\multicolumn{#3}{){\columncolor{#2}}#4}{#1}}
\newenvironment{reflist}{%
  \begin{raggedright}\begin{list}{}
  {%
   \setlength{\topsep}{0pt}%
   \setlength{\rightmargin}{0.25in}%
   \setlength{\itemsep}{0pt}%
   \setlength{\itemindent}{0pt}%
   \setlength{\parskip}{0pt}%
   \setlength{\parsep}{2pt}%
   \def\makelabel##1{\itshape ##1}}%
  }
  {\end{list}\end{raggedright}}
\newenvironment{sansreflist}{%
  \begin{raggedright}\begin{list}{}
  {%
   \setlength{\topsep}{0pt}%
   \setlength{\rightmargin}{0.25in}%
   \setlength{\itemindent}{0pt}%
   \setlength{\parskip}{0pt}%
   \setlength{\itemsep}{0pt}%
   \setlength{\parsep}{2pt}%
   \def\makelabel##1{\upshape ##1}}%
  }
  {\end{list}\end{raggedright}}
\newenvironment{specHead}[2]%
 {\vspace{20pt}\hrule\vspace{10pt}%
  \phantomsection\label{#1}\markright{#2}%

  \pdfbookmark[2]{#2}{#1}%
  \hspace{-0.75in}{\bfseries\fontsize{16pt}{18pt}\selectfont#2}%
  }{}
      \def\TheFullDate{2015-05-15 (revised: 15 May 2015)}
\def\TheID{\makeatother }
\def\TheDate{2015-05-15}
\title{Plasma Uric Acid Levels in Relation to Plasma Cholesterol Levels in Type-2 Diabetes Mellitus}
\author{}\makeatletter 
\makeatletter
\newcommand*{\cleartoleftpage}{%
  \clearpage
    \if@twoside
    \ifodd\c@page
      \hbox{}\newpage
      \if@twocolumn
        \hbox{}\newpage
      \fi
    \fi
  \fi
}
\makeatother
\makeatletter
\thispagestyle{empty}
\markright{\@title}\markboth{\@title}{\@author}
\renewcommand\small{\@setfontsize\small{9pt}{11pt}\abovedisplayskip 8.5\p@ plus3\p@ minus4\p@
\belowdisplayskip \abovedisplayskip
\abovedisplayshortskip \z@ plus2\p@
\belowdisplayshortskip 4\p@ plus2\p@ minus2\p@
\def\@listi{\leftmargin\leftmargini
               \topsep 2\p@ plus1\p@ minus1\p@
               \parsep 2\p@ plus\p@ minus\p@
               \itemsep 1pt}
}
\makeatother
\fvset{frame=single,numberblanklines=false,xleftmargin=5mm,xrightmargin=5mm}
\fancyhf{} 
\setlength{\headheight}{14pt}
\fancyhead[LE]{\bfseries\leftmark} 
\fancyhead[RO]{\bfseries\rightmark} 
\fancyfoot[RO]{}
\fancyfoot[CO]{\thepage}
\fancyfoot[LO]{\TheID}
\fancyfoot[LE]{}
\fancyfoot[CE]{\thepage}
\fancyfoot[RE]{\TheID}
\hypersetup{citebordercolor=0.75 0.75 0.75,linkbordercolor=0.75 0.75 0.75,urlbordercolor=0.75 0.75 0.75,bookmarksnumbered=true}
\fancypagestyle{plain}{\fancyhead{}\renewcommand{\headrulewidth}{0pt}}

\date{}
\usepackage{authblk}

\providecommand{\keywords}[1]
{
\footnotesize
  \textbf{\textit{Index terms---}} #1
}

\usepackage{graphicx,xcolor}
\definecolor{GJBlue}{HTML}{273B81}
\definecolor{GJLightBlue}{HTML}{0A9DD9}
\definecolor{GJMediumGrey}{HTML}{6D6E70}
\definecolor{GJLightGrey}{HTML}{929497} 

\renewenvironment{abstract}{%
   \setlength{\parindent}{0pt}\raggedright
   \textcolor{GJMediumGrey}{\rule{\textwidth}{2pt}}
   \vskip16pt
   \textcolor{GJBlue}{\large\bfseries\abstractname\space}
}{%   
   \vskip8pt
   \textcolor{GJMediumGrey}{\rule{\textwidth}{2pt}}
   \vskip16pt
}

\usepackage[absolute,overlay]{textpos}

\makeatother 
      \usepackage{lineno}
      \linenumbers
      
\begin{document}

             \author[1]{Goudappla Prashanthkumar  }

             \author[2]{Kashinath R  T}

             \author[3]{Nagendra  S}

             \affil[1]{  }

\renewcommand\Authands{ and }

\date{\small \em Received: 6 April 2015 Accepted: 5 May 2015 Published: 15 May 2015}

\maketitle


\begin{abstract}
        


Uric acid, the prime end product of purine catabolism, has been implicated in diabetes mellitus as well as in hyperlipidemias. Its significance in diabetic hypercholesterolemia is not established. A study was under taken to assess the relationship of plasma cholesterol with plasma uric acid in type-2 diabetes mellitus subjects. A fasting blood sample was collected from normal as well as type-2 diabetic subjects, the separated plasma was employed for the estimation of glucose, cholesterol and uric acid levels. It is observed that there is a proportional rise in uric acid in type-2 diabetic subjects, suggesting that plasma uric acid levels along with total cholesterol levels aids to asses the diabetes induced dyslipidemia as well as to control the diabetic dyslipidemia induced complications in type-2 diabetes mellitus.

\end{abstract}


\keywords{plasma uric acid, plasma cholesterol, type-2 diabetes mellitus, vascular complications.}

\begin{textblock*}{18cm}(1cm,1cm) % {block width} (coords) 
\textcolor{GJBlue}{\LARGE Global Journals \LaTeX\ JournalKaleidoscope\texttrademark}
\end{textblock*}

\begin{textblock*}{18cm}(1.4cm,1.5cm) % {block width} (coords) 
\textcolor{GJBlue}{\footnotesize \\ Artificial Intelligence formulated this projection for compatibility purposes from the original article published at Global Journals. However, this technology is currently in beta. \emph{Therefore, kindly ignore odd layouts, missed formulae, text, tables, or figures.}}
\end{textblock*}


\let\tabcellsep& 	 	 		 
\section[{Introduction}]{Introduction}\par
ric acid, the prime end product of purine catabolism is implicated in diabetes mellitus. Suggesting a possible role of insulin in nucleotide metabolism. It has been claimed by few research workers that plasma uric acid levels are elevated in diabetes mellitus \hyperref[b0]{(1)}\hyperref[b1]{(2)}\hyperref[b2]{(3)}\hyperref[b3]{(4)}\hyperref[b4]{(5)}\hyperref[b5]{(6)}\hyperref[b6]{(7)}\hyperref[b7]{(8)}\hyperref[b9]{(9)}\hyperref[b10]{(10)}\hyperref[b11]{(11)}.In earlier report from our laboratory the uric acid elevation in diabetes mellitushas been conclusively established as due to raised nucleotide catabolism \hyperref[b12]{(12)}. in type 2 diabetic subjects to establish the inter relationship of plasma uric acid levels with diabetes induced Hypercholesterolemia.\par
The type-2 diabetic subjects (both male and females) attending the medical Out Patient Department of Subbaiah Medical College Hospital, Purle, Shimoga. were randomly selected, similarly normal subjects (both male and females)\par
were randomly taken from employees of medical college and hospital. Fasting blood samples were collected from normal as well as selected diabetic subjects (The subjects having orthopedic \& renal problems were excluded from the study) and were allowed to clot and plasma samples were separated by centrifugation at 3500rpm for 8mins, the separated samples were employed for estimation of Total Cholesterol \hyperref[b16]{(15)} , Uric acid \hyperref[b17]{(16)} and Glucose \hyperref[b18]{( 17)}.\par
The results obtained were statistically analyzed using student t-test. 
\section[{III.}]{III.} 
\section[{Results}]{Results}\par
The diabetic subjects were divided into two groups depending on their plasma cholesterol level. Group 1-NormoCholesterolemic Diabetic Subjectshaving plasma cholesterol levels<200mg/dl and Group 2-HypercholsterolemicDiabetic Subjects-having plasma cholesterol levels >200mg/dl.The results obtained in the present study are given in \hyperref[tab_1]{Table-1 and Table-2} Table  {\ref -}1 narrates fasting plasma glucose levels as well as plasma uric acid levels in normal subjects and in type-2 diabetic subjects. It is evident from the table that uric acid levels are significantly elevated (p<0.001) in type2 diabetic subjects as compared to normal.\par
Table-2 depicts the values of plasma total cholesterol and plasma uric acid levels in group1 diabetic subjects (plasma cholesterol<200mg/dl) and in group2 diabetic subjects (plasma cholesterol >200mg/dl). It is clear from the table that there is significant elevation in plasma uric acid levels in hypercholesterolemic subjects as compared to normal cholesterolemic subjects. The hyperglycemia observed in diabetes mellitus if not controlled may lead to various life threatening complications including micro and macro vascular diseases \hyperref[b14]{(13)}. A proper control, hence becomes the priority of management of diabetes mellitus. It is known that in dyslipidemia, one of the general complications ofdiabetes mellitusplasmatotal cholesterol levels are seen elevated \hyperref[b15]{(14)}. Further it is shown by few research workers thatplasma uric acid levels are elevated in hyperlipidemias including hypercholesterolemia. The present work was carried out 
\section[{Materials and Methods}]{Materials and Methods} 
\section[{II.}]{II.}\par
Goudappala Prashanthkumar 1 , Nagendra S 2 \& Kashinath R T 3 IV. 
\section[{Discussion}]{Discussion}\par
Uric acid, the end product of purine catabolism in humans, has been suggested to have a close relationship with cardiovascular diseases , where an increase in plasma uric acid levels have been observed \hyperref[b19]{(18)}\hyperref[b21]{(19)}\hyperref[b22]{(20)}. Further it has been shown that plasma uric acid levels are elevated in hyperlipidemia specifically hypertriglyceridemia \hyperref[b23]{(21)}\hyperref[b24]{(22)}\hyperref[b25]{(23)}. The elevated plasma uric acid levels observed in our present studies are in agreement with our earlier reports(1-11) as well as with earlier findings (12) and the rise observed may be due to increased purine turnover as suggested in our earlier communication from our laboratory \hyperref[b12]{(12)} or may be due to diabetic dyslipidemia induced increased vascular damage(13) A parallel increase in plasma uric acid levels along with plasma cholesterol levels in the present study in type-2 diabetic subjects suggests a possible relationship between plasma uric acid level and plasma lipid profile specifically plasma cholesterol. Kelley and Palella \hyperref[b26]{(24)} have observed a rise in uric acid levels in hypertriglyceridemia ,hypertension, obesity and diabetes mellitus \hyperref[b26]{(24,}\hyperref[b27]{25)} The increase observed in uric acid levels in the present studies indicates a definite rise in uric acid levels in diabetic subjects with a close relationship to cholesterol levels. The observed increase in uric acid levels in type-2 diabetic subjects indicates a positive relationship of uric acid levels with cholesterol levels in type-2 subjects( refer Table-2) suggesting, the rise in uric acid parallel increases in cholesterol levels. Many life threatening complications of type-2 diabetes mellitus specifically micro angiopathy have been attributed to diabetes induced dyslipidemia. As there is a parallel rise in uric acid along with cholesterol levels in type-2 diabetic subjects an estimation of uric acid levels in serum may be an additional significant criteria to assess  3. Statistical significance is given by * p>0.05, ** p>0.01, *** p>0. \begin{figure}[htbp]
\noindent\textbf{}\includegraphics[]{image-2.png}
\caption{\label{fig_0}U}\end{figure}
  \begin{figure}[htbp]
\noindent\textbf{1} \par 
\begin{longtable}{P{0.2091269841269841\textwidth}P{0.37103174603174605\textwidth}P{0.2698412698412698\textwidth}}
\tabcellsep Fasting Plasma Glucose\tabcellsep Uric acid\\
\tabcellsep mg/dl\tabcellsep mg/dl\\
Normals\tabcellsep 103.82\tabcellsep 3.688\\
(11)\tabcellsep +\tabcellsep +\\
\tabcellsep 13.80\tabcellsep 0.732\\
Diabetics\tabcellsep 196.93 ***\tabcellsep 7.033 ***\\
(58)\tabcellsep +\tabcellsep +\\
\tabcellsep 15.03\tabcellsep 1.700\\
Note:\tabcellsep \tabcellsep \\
1.\tabcellsep \tabcellsep \end{longtable} \par
 
\caption{\label{tab_0}Table 1 :}\end{figure}
 \begin{figure}[htbp]
\noindent\textbf{2} \par 
\begin{longtable}{P{0.3\textwidth}P{0.06818181818181818\textwidth}P{0.03636363636363636\textwidth}P{0.23181818181818178\textwidth}P{0.21363636363636362\textwidth}}
\tabcellsep \tabcellsep \tabcellsep Plasma Cholesterol\tabcellsep Plasma Uric acid\\
\tabcellsep \tabcellsep \tabcellsep mg/dl\tabcellsep mg/dl\\
Normo\tabcellsep \tabcellsep \tabcellsep 159.56\tabcellsep 5.676\\
\multicolumn{3}{l}{Cholesterolemic Diabetic subjects}\tabcellsep +\tabcellsep +\\
(25)\tabcellsep \tabcellsep \tabcellsep 22.99\tabcellsep 0.829\\
Hyper\tabcellsep Cholesterolemic\tabcellsep Diabetic\tabcellsep 252.90 ***\tabcellsep 8.203 ***\\
subjects\tabcellsep \tabcellsep \tabcellsep +\tabcellsep +\\
(29)\tabcellsep \tabcellsep \tabcellsep 40.69\tabcellsep 1.348\\
Note:\tabcellsep \tabcellsep \tabcellsep \tabcellsep \\
1.\tabcellsep \tabcellsep \tabcellsep \tabcellsep \end{longtable} \par
 
\caption{\label{tab_1}Table 2 :}\end{figure}
 			\footnote{Plasma Uric Acid Levels in Relation to Plasma Cholesterol Levels in Type-2 Diabetes Mellitus} 		 		\backmatter  			 \par
beneficial in type-2 diabetic subjects to asses the diabetic dyslipidemia induced vascular complications.			 			  				\begin{bibitemlist}{1}
\bibitem[Diabetes]{b8}\label{b8} 	 		\textit{},  		 			Diabetes 		.  	 	 		\textit{Diabetologia}  		12 p. .  	 
\bibitem[ Jama]{b20}\label{b20} 	 		\textit{},  	 	 		\textit{Jama}  		283  (18)  p. .  	 
\bibitem[Herman and Medelie ()]{b7}\label{b7} 	 		\textit{},  		 			J B Herman 		,  		 			J Medelie 		.  		1976.  	 
\bibitem[Kashinath and Nagendra S &srinivas ()]{b12}\label{b12} 	 		\textit{},  		 			R T Kashinath 		,  		 			S Nagendra S \&srinivas 		.  		2014.  	 
\bibitem[Wang et al. ()]{b4}\label{b4} 	 		‘A prospective study on relationship between blood uric acid levels, insulin sensitivity and insulin resistance’.  		 			M Wang 		,  		 			O Zhao 		,  		 			W Wang 		,  		 			J \& Lin 		,  		 			S Lin 		.  	 	 		\textit{Chinese Journal of Internal Medicine}  		2007. 46 p. .  	 
\bibitem[Gochman and Schmitz ()]{b17}\label{b17} 	 		‘Automated determination of uric acid, with use of auricaseperoxidase system’.  		 			N Gochman 		,  		 			J M Schmitz 		.  	 	 		\textit{Clinical chemistry}  		1971. 17  (12)  p. .  	 
\bibitem[Gadi and &samaha ()]{b15}\label{b15} 	 		‘Dyslipidemia in type 2 diabetes mellitus’.  		 			R Gadi 		,  		 			F F \&samaha 		.  	 	 		\textit{Current diabetes reports}  		2007. 7  (3)  p. .  	 
\bibitem[Quinones et al. ()]{b5}\label{b5} 	 		‘Effect of insulin on uric acid excretion in humans’.  		 			G A Quinones 		,  		 			A Natali 		,  		 			S Baldi 		,  		 			S Frascerra 		,  		 			G Sanna 		,  		 			D Ciociaro 		,  		 			Etal 		.  	 	 		\textit{Am. J. Endocrinol. Metab}  		1995. 268 p. .  	 
\bibitem[Roeschlau et al. ()]{b16}\label{b16} 	 		‘Enzymatic determination of total cholesterol in serum’.  		 			P Roeschlau 		,  		 			E Bernt 		,  		 			W Gruber 		.  	 	 		\textit{Z KlinChemKlinBiochem}  		1974. 12 p. 226.  	 
\bibitem[Lott and Turner ()]{b18}\label{b18} 	 		‘Evaluation of Trinder's glucose oxidase method for measuring glucose in serum and urine’.  		 			J A Lott 		,  		 			K Turner 		.  	 	 		\textit{Clinical chemistry}  		1975. 21  (12)  p. .  	 
\bibitem[Kertes and J &jhonson T M ()]{b1}\label{b1} 	 		\textit{Evidence based Eye care. Philidelphia},  		 			P Kertes 		,  		 			J \&jhonson T M 		.  		2007. Lippincott Williams \& Wilkins.  	 
\bibitem[Boyko et al. ()]{b11}\label{b11} 	 		‘Features of the metabolic syndrome predict higher risk of diabetes and impaired glucose tolerance -a prospective study in Maurtius’.  		 			E J Boyko 		,  		 			M De Courten 		,  		 			P Z Zimmer 		,  		 			P Chitson 		,  		 			K Tonmilhetoj\&alberti 		.  	 	 		\textit{Diabetes Care}  		2000. 23 p. .  	 
\bibitem[Kelley and Palella ()]{b26}\label{b26} 	 		\textit{Gout and Other Disorders of Purine Metabolism. Harrison's Principles of Internal Medicine},  		 			N Kelley 		,  		 			T D Palella 		.  		2001. New York: McGraw Hill Book Company. 2 p. .  	 	 (15th Ed) 
\bibitem[Hyperuricemia in Type 2 Diabetes Mellitus Global Journal of Medical Research]{b13}\label{b13} 	 		‘Hyperuricemia in Type 2 Diabetes Mellitus’.  	 	 		\textit{Global Journal of Medical Research}  		14  (3) .  	 
\bibitem[Butturini and Coscelli ()]{b2}\label{b2} 	 		‘Insulin release in hyperuricemic patients’.  		 			U Butturini 		,  		 			C Coscelli 		.  	 	 		\textit{Acta. Diab Lat}  		1977. 14 p. .  	 
\bibitem[Medelie et al. ()]{b6}\label{b6} 	 		‘Major factors in the development of diabetes mellitus in 10000 men’.  		 			J H Medelie 		,  		 			C M Papier 		,  		 			U \& Goldbourt 		,  		 			J Herman 		.  	 	 		\textit{Arch. Int. Med}  		1975. 135 p. .  	 
\bibitem[Milionis and &elisaf ()]{b27}\label{b27} 	 		\textit{Management of hypertension and dyslipidaemia in patients},  		 			H J Milionis 		,  		 			M S \&elisaf 		.  		2000.  	 
\bibitem[Fowler ()]{b14}\label{b14} 	 		‘Microvascular and macrovascular complications of diabetes’.  		 			M J Fowler 		.  	 	 		\textit{Clinical diabetes}  		2008. 26  (2)  p. .  	 
\bibitem[Toumilehto et al. ()]{b9}\label{b9} 	 		‘Plasma uric acid and its association with diabetes mellitus and some biological parameters in biracial population of Fizi’.  		 			J Toumilehto 		,  		 			P Zimmet 		,  		 			E Wolf 		,  		 			R Taylor 		,  		 			P \& Ram 		,  		 			H King 		.  	 	 		\textit{Am. J. Epidemiol}  		1988. 127 p. .  	 
\bibitem[Conen et al. ()]{b23}\label{b23} 	 		‘Prevalence of hyperuricemia and relation of serum uric acid with cardiovascular risk factors in a developing country’.  		 			D Conen 		,  		 			V Wietlisbach 		,  		 			P Bovet 		,  		 			C Shamlaye 		,  		 			W Riesen 		,  		 			F Paccaud 		,  		 			M \&burnier 		.  	 	 		\textit{BMC public health}  		2004. 4  (1)  p. 9.  	 
\bibitem[Bonora et al. ()]{b25}\label{b25} 	 		‘Relationship of uric acid concentration to cardiovascular risk factors in young men. Role of obesity and central fat distribution. The Verona Young Men Atherosclerosis Risk Factors Study’.  		 			E Bonora 		,  		 			G Targher 		,  		 			M B Zenere 		,  		 			F Saggiani 		,  		 			V Cacciatori 		,  		 			F Tosi 		,  		 			. . \&muggeo 		,  		 			M 		.  	 	 		\textit{International journal of obesity and related metabolic disorders: journal of the International Association for the Study of Obesity}  		1996. 20  (11)  p. .  	 
\bibitem[Fang and Alderman ()]{b19}\label{b19} 	 		\textit{Serum uric acid and cardiovascular mortality: the NHANES I epidemiologic follow-up study},  		 			J Fang 		,  		 			M H Alderman 		.  		2000. 1971.  	 
\bibitem[Culleton et al. ()]{b22}\label{b22} 	 		‘Serum uric acid and risk for cardiovascular disease and death: the Framingham Heart Study’.  		 			B F Culleton 		,  		 			M G Larson 		,  		 			W B Kannel 		,  		 			D Levy 		.  	 	 		\textit{Annals of internal medicine}  		1999. 131  (1)  p. .  	 
\bibitem[Nakanishi et al. ()]{b10}\label{b10} 	 		‘Serum uric acid and risk for development of hypertension and impaired fasting glucose or type II diabetes in Japanese male office workers’.  		 			N Nakanishi 		,  		 			M Okamoto 		,  		 			H Yoshida 		,  		 			Y Matsuo 		,  		 			K Suzuki K \&tatara 		.  	 	 		\textit{Eur. J. Epidemiol}  		2003. 18 p. .  	 
\bibitem[Sinagra et al. ()]{b3}\label{b3} 	 		‘Serum uric acid, insulin secretion and resistance in non-hyperuricemia and hyperuricemic obese female subjects’.  		 			D Sinagra 		,  		 			D Greco 		,  		 			A Scarpitta 		.  	 	 		\textit{Int. J. Obes. Relat. Metab.Disord}  		1996. 20 p. .  	 
\bibitem[Nakanishi et al. ()]{b24}\label{b24} 	 		‘Serum uric acid: correlation with biological, clinical and behavioral factors in Japanese men’.  		 			N Nakanishi 		,  		 			K Suzuki 		,  		 			H Kawashimo 		,  		 			K Nakamura 		,  		 			K \&tatara 		.  	 	 		\textit{JapanEpidemiologicalAssociation}  		1999. 9  (2)  p. .  	 	 (Journal of epidemiology) 
\bibitem[Niskanen et al. ()]{b21}\label{b21} 	 		‘Uric acid level as a risk factor for cardiovascular and all-cause mortality in middleaged men: a prospective cohort study’.  		 			L K Niskanen 		,  		 			D E Laaksonen 		,  		 			K Nyyssönen 		,  		 			G Alfthan 		,  		 			H M Lakka 		,  		 			T A Lakka 		,  		 			J T \&salonen 		.  	 	 		\textit{Archives of internal medicine}  		2004. 164  (14)  p. .  	 
\bibitem[Kashinath ()]{b0}\label{b0} 	 		‘Whole blood uric acid levels in diabetics with or without lipaemia’.  		 			R Kashinath 		.  	 	 		\textit{J. Mys. Med. Assoc}  		1972. 36 p. .  	 
\end{bibitemlist}
 			 		 	 
\end{document}
